Anti-IL-17 Agents amusement Efficacy in Psoriasis Medscape April 5, 2012 — Ixekizumab and brodalumab, ii humanized monoclonal antibodies that target the interleukin xvii (IL-17) cytokine pathway, significantly improved symptoms of disease of the skin relative to placebo, according to the findings of two 12-week, ... Amgen Psoriasis Candidate Impresses Zacks.com Brodalumab For Moderate To Severe Psoriasis Moving Into Phase III Medical tidings Today all 4 tidings articles » Link To Article
No comments:
Post a Comment